Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

Nucleophosmin 1 (NPM1) is an oligomeric, nucleolar phosphoprotein that functions as a molecular chaperone for both proteins and nucleic acids. NPM1 is mutated in approximately one-third of patients with AML. The mutant NPM1c+ contains a 4-base insert that results in extra C-terminal residues encoding a nuclear export signal, which causes NPM1c+ to be localized in the cytoplasm. Here, we determined the effects of targeting NPM1 in cultured and primary AML cells. Treatment with siRNA to NPM1 induced p53 and p21, decreased the percentage of cells in S-phase of the cell cycle, as well as induced differentiation of the AML OCI-AML3 cells that express both NPMc+ and unmutated NPM1. Notably, knockdown of NPM1 by shRNA abolished lethal AML phenotype induced by OCI-AML3 cells in NOD/SCID mice. Knockdown of NPM1 also sensitized OCI-AML3 to all-trans retinoic acid (ATRA) and cytarabine. Inhibition of NPM1 oligomerization by NSC348884 induced apoptosis and sensitized OCI-AML3 and primary AML cells expressing NPM1c+ to ATRA. This effect was significantly less in AML cells coexpressing FLT3-ITD, or in AML or normal CD34+ progenitor cells expressing wild-type NPM1. Thus, attenuating levels or oligomerization of NPM1 selectively induces apoptosis and sensitizes NPM1c+ expressing AML cells to treatment with ATRA and cytarabine.

[1]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[2]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Bhalla,et al.  Heat Shock Protein 90 Inhibition Depletes TrkA Levels and Signaling in Human Acute Leukemia Cells , 2010, Molecular Cancer Therapeutics.

[4]  Kevin S. Smith,et al.  GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. , 2010, Cancer cell.

[5]  J. Clohessy,et al.  The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. , 2010, Blood.

[6]  A. Look,et al.  Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. , 2010, Blood.

[7]  R. Hills,et al.  The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. , 2010, Blood.

[8]  W. Du,et al.  NPM phosphorylation stimulates Cdk1, overrides G2/M checkpoint and increases leukemic blasts in mice. , 2010, Carcinogenesis.

[9]  R. Arceci.  The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA , 2010 .

[10]  B. Falini,et al.  Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives , 2009, Current opinion in oncology.

[11]  Huidong Shi,et al.  Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.

[12]  Yu-Long Hu,et al.  HOXA9 Modulates Its Oncogenic Partner Meis1 To Influence Normal Hematopoiesis , 2009, Molecular and Cellular Biology.

[13]  T. Kundu,et al.  Acetylated NPM1 Localizes in the Nucleoplasm and Regulates Transcriptional Activation of Genes Implicated in Oral Cancer Manifestation , 2009, Molecular and Cellular Biology.

[14]  P. Atadja,et al.  Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells , 2009, Cancer biology & therapy.

[15]  D. Alonso,et al.  Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity , 2009, Molecular Cancer Therapeutics.

[16]  Daniel Nowak,et al.  Differentiation therapy of leukemia: 3 decades of development. , 2009, Blood.

[17]  Daniel G Tenen,et al.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Fröhling,et al.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B , 2009, Haematologica.

[19]  M. Bycroft,et al.  Structural Consequences of Nucleophosmin Mutations in Acute Myeloid Leukemia* , 2008, Journal of Biological Chemistry.

[20]  W. Qi,et al.  NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells , 2008, Oncogene.

[21]  K. Nagata,et al.  Transcription Regulation of the rRNA Gene by a Multifunctional Nucleolar Protein, B23/Nucleophosmin, through Its Histone Chaperone Activity , 2008, Molecular and Cellular Biology.

[22]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[23]  M. Okuwaki,et al.  The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. , 2007, Journal of biochemistry.

[24]  J. Downing,et al.  Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias , 2007, Leukemia.

[25]  J. Chen,et al.  Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival , 2007, Proceedings of the National Academy of Sciences.

[26]  Brunangelo Falini,et al.  Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. , 2007, Haematologica.

[27]  Brunangelo Falini,et al.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.

[28]  T. Naoe,et al.  Nucleophosmin: A versatile molecule associated with hematological malignancies , 2006, Cancer science.

[29]  Pier Paolo Pandolfi,et al.  Nucleophosmin and cancer , 2006, Nature Reviews Cancer.

[30]  M. Dai,et al.  Nucleophosmin Is Essential for Ribosomal Protein L5 Nuclear Export , 2006, Molecular and Cellular Biology.

[31]  X. Wang,et al.  Nucleophosmin and human cancer. , 2006, Cancer detection and prevention.

[32]  N. Bolli,et al.  Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin , 2005, Leukemia.

[33]  P. Pandolfi,et al.  Role of nucleophosmin in embryonic development and tumorigenesis , 2005, Nature.

[34]  T. Kundu,et al.  Human Histone Chaperone Nucleophosmin Enhances Acetylation-Dependent Chromatin Transcription , 2005, Molecular and Cellular Biology.

[35]  Natalia Meani,et al.  Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.

[36]  Marie S. Hasemann,et al.  Loss of C/EBPα cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage , 2005, The Journal of experimental medicine.

[37]  G. Wang,et al.  Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. , 2005, Blood.

[38]  T. Ohta,et al.  Nucleophosmin/B23 Is a Candidate Substrate for the BRCA1-BARD1 Ubiquitin Ligase* , 2004, Journal of Biological Chemistry.

[39]  S. Kurki,et al.  Nucleophosmin, HDM2 and p53: Players in UV Damage Incited Nucleolar Stress Response , 2004, Cell cycle.

[40]  Charles J. Sherr,et al.  Physical and Functional Interactions of the Arf Tumor Suppressor Protein with Nucleophosmin/B23 , 2004, Molecular and Cellular Biology.

[41]  M. Okuda.  The role of nucleophosmin in centrosome duplication , 2002, Oncogene.

[42]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[43]  Pier Giuseppe Pelicci,et al.  Nucleophosmin regulates the stability and transcriptional activity of p53 , 2002, Nature Cell Biology.

[44]  K. Calvo,et al.  Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: Potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  H. F. Horn,et al.  Specific Phosphorylation of Nucleophosmin on Thr199 by Cyclin- dependent Kinase 2-Cyclin E and Its Role in Centrosome Duplication* , 2001, The Journal of Biological Chemistry.

[46]  C. Hsu,et al.  Over‐expression of nucleophosmin/B23 decreases the susceptibility of human leukemia HL‐60 cells to retinoic acid‐induced differentiation and apoptosis , 2000, International journal of cancer.

[47]  M. Olson,et al.  Mapping the Functional Domains of Nucleolar Protein B23* , 2000, The Journal of Biological Chemistry.

[48]  K. Pulford,et al.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis , 1997, Molecular and cellular biology.

[49]  S. Corey,et al.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. , 1996, Blood.

[50]  S. Raimondi,et al.  The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. , 1996, Oncogene.

[51]  K. Bhalla,et al.  High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. , 1993, Blood.